Intragastric Balloon Market By Product Type (Single Balloon Systems, Dual Balloon Systems, Triple Balloon Systems), By Filling Material (Saline-filled Balloons, Gas-filled Balloons, Combination-Filled Balloons), By Insertion Type (Endoscopic Insertion, Surgical Insertion, Non-Endoscopic Insertion), By Material (Silicone Balloon, Polyurethane Balloon, Hybrid), By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Intragastric Balloon market accounted for USD 48.5 Billion in 2024 and is expected to reach USD 126.4 Billion by 2035, growing at a CAGR of around 9.1% between 2025 and 2035. The segment of the healthcare industry that is being addressed with the intragastric balloon market is the part of the industry that provides products and services related to weight loss technologies in the form of a balloon that is placed into the stomach. This is a noninvasive treatment mainly used to aid weight loss since it is believed it will limit stomach capacity and therefore make patients feel full even after taking a small quantity of food.

Growth has been occasioned by wage increases, a rise in obesity levels, and the need for less invasive procedures than those offered by conventional bariatric surgery. They come in different types of balloons and from different manufacturing companies, for both short- and long-term use. The market is also highly influenced by technological improvements in the medical area, achieving broader acceptance and generally growing health consciousness. There are certain disadvantages: one of them is the appearance of various complications, the second is the imperativeness of dieting and changes in the mode of life, and the third is still important—the method is temporary. North America and Europe, which are highly affected by obesity, have a major influence on the market growth. With advances in the balloon material utilized and favorable patient results, the intragastric balloon market appears potentially in the future.

Report Scope:

Market Dynamics

Rising obesity prevalence increases demand for non-surgical weight loss solutions.

A growing incidence of obesity also contributes to a growing desire for non-surgical approaches to the treatment of obesity, which has a positive effect on the intragastric balloon market. As obesity started to cut across the population, making more and more people obese, more people are looking for some other natural ways to lose weight without passing through surgeries. Intragastric balloons, in particular, are good for those needing a non-surgical method of weight loss via taking up the space occupied by foods, thus reducing appetite. They are excited about this process, especially if they are unable to undergo traditional weight loss procedures. Healthcare agencies such as the CDC have highlighted rising obesity trends and argued that leg vein lipolysis could fill a void in non-surgical weight loss solutions. With an increasing number of patients seeking therapies like intragastric balloons, there is room for expansion in this sector.

Advancements in intragastric balloon technologies improve safety and effectiveness.

The changes in the intragastric balloon technologies are beneficial in increasing the growth of the intragastric balloon market because they increase safety and efficiency for the patients. The procedure itself has changed over the years, and now, balloons are made of better material, can be placed with better techniques, and monitored better; thus, the risks are minimal. They result in fewer complications and a better feel for the patients, thus making the chances of weight loss higher. Thus, increasing numbers of people opt for it to lose weight, especially those who refuse surgery.

Organizations such as the National Institutes of Health (NIH) have identified these technological developments in their research, and there is an apparent change of fortunes regarding the efficacy of intragastric balloons. These improvements, however, not only enable better patient outcomes but also allow for the expansion and propensity of the market as the procedure becomes embraced by a larger market.

Risk of complications like balloon deflation and gastrointestinal side effects.

The complications involved with balloon deflation and upset gastrointestinal tracts act as restraints for the intragastric balloon market. Intragastric balloons are also known to be relatively safe and effective for weight loss; however, risks discourage certain patients from undergoing the procedure. As with other types of foreign bodies, deflation of a swallowed balloon can cause complications such as obstruction of the gastrointestinal tract or migration of the balloon either upwards or downwards, which may necessitate surgery.

Moreover, GI side effects such as nausea, vomiting, abdominal pain, and bloating can occur during the initial weeks and may, for some patients, persist as mild to moderate interferences with comfort during cancer therapy. Such risks, coordinating and controlling requirements throughout the process, may slow down the usage of the technology and give rise to concern among practitioners and consumers in the healthcare sector. Therefore, the likelihood of issues arising is a major factor that contributes to the market’s tendency toward limited growth where the intragastric balloon is concerned.

Expansion into untapped markets with increasing obesity rates.

The growing obesity ratio, late entrants, and availability of unexplored economic markets also pose a strong threat in the intragastric balloon market. Thus, with obesity being an emerging threat to the global population, many territories, especially the emergent ones, are witnessing increasing rates of obesity-associated diseases. In particular, these markets offer a significant unmet need for the patient population who may require other weight loss solutions than bariatric surgery, such as intragastric balloons. The opportunities that the market has for growth can be seen in the fact that there seems to be an increasing need for effective, safe, more affordable, and non-invasive weight loss solutions in these regions. Furthermore, as people have a better grasp of the obesogenic hazard and its consequences, they are more optimistic about finding effective weight loss options. By entering these underserved sectors, manufacturers and healthcare providers may address the requirements of a new population, boosting the market and improving global health.

Development of biodegradable and smart balloons with enhanced safety profiles.

Introducing biodegradable and smart balloons with improved safety features appears to be the most attractive segment in the intragastric balloon market. The biodegradable balloons provide the additional benefit of dissolving over time, thus making the need for removal surgery and the risks related thereto. These outcomes are achievable, which makes this innovation led to better patient compliance and satisfaction.

Also, smarter balloons with pressure, positioning, as well as the patient’s response sensors may improve safety and utility. These technological developments make it possible to monitor progress and make corrections for the best results in real-time data tracking. The cheaper and completely biodegradable balloons entail lower risks for patients categorically interested in weight loss, gaining a larger audience. When there is a technology change, it results in a higher degree of uptake, and as a result, turnover increases in the intragastric balloon market.

Industry Experts Opinion

"Intragastric balloons have become an essential part of the weight management toolkit. They offer a temporary but impactful solution for patients needing to jumpstart their weight loss journey, especially those who may not qualify for or are hesitant about surgical interventions. The key to long-term success lies in combining the procedure with comprehensive lifestyle counselling and support."

• Dr. Karen Lewis, MD, Director of Bariatric Medicine at Global Health Institute

Segment Analysis

Based on the product type, the Intragastric Balloon market is classified into Single Balloon Systems, Dual Balloon Systems, and Triple Balloon Systems. The single balloon system segment holds the largest share of the intragastric balloon market. It has become dominant due to the following reasons: it is easy to use, cheap and has been reputed to help people lose weight. Single balloon systems are less invasive and are known to be safer than surgical methods for weight loss; thus, more patients take it. When used, their overall design is convenient for placement and removal, factors that minimize complications and maximize the comfort of the patients.

In addition, clinical evidence of the effectiveness in attaining sizeable weight loss supplements their market standing. By having regulatory approval and using new products that his main competitors offer, this segment has high adoption rates. Furthermore, other factors that contributed to their importance include increased incidence of obesity, enhanced public awareness concerning obesity surgery, and the desire for less invasive procedures that can be offered as outpatient procedures. Adding it all up makes the single-balloon systems a more favorable choice for both the healthcare provider and the patients, which keeps them ruling the market.

Based on the filling material, the intragastric balloon market is classified into saline-filled balloons, gas-filled balloons, and combination-filled balloons. The saline-filled balloon segment is currently the largest in the intragastric balloon market. Such dominance can be attributed to the passiveness of this drug in the market and its safety and efficacy in promoting weight loss. Saline-filled balloons are nevertheless most popular since more people find they offer a more predictable, controllable method of inflation for ideal weight loss.

These balloons are visual under imaging, therefore increasing ease in monitoring, and it is safe to place and remove them. This is because most healthcare providers have endorsed them due to clinical research that has provided proof that they help lower body weight within a given period. In addition, low-volume, saline-filled balloons are said to create a lower incidence of gas-related discomfort and improve patient compliance. Market growth is supported by improved balloon design and the growing number of regulatory approvals. Higher incidence of obesity and people’s increased awareness of non-surgical treatments encourage the utilization of these devices, which, in turn, strengthen the leaders’ positions in the market.

Regional Analysis

The North American intragastric balloon market has a very high growth rate due to the high incidence of obesity and an increasing customer interest in non-surgical procedures for weight reduction. The region includes strong healthcare systems, availability of experienced human resource partners, and active research and development. High approval and enhanced recognition of innovative solutions also explain the market’s growth, complemented by proper legislative acts.

Increasing consumer inclination toward non-surgical solutions for weight reduction and the escalating costs of medical care are motivating the intragastric balloons’ demand. It is also driven by the rising collaboration between healthcare providers and manufacturers to expand service delivery. Furthermore, awareness campaigns and promotional activities are most helpful in encouraging the adoption, and hence North America is considered to be a key market in this segment.

The Asia Pacific region has the fastest-growing intragastric balloon market because of the rising obesity rates and the awareness regarding weight loss solutions. A rising middle class in the region and increased disposable income mean increased demand for weight loss solutions that are less invasive. Favorable trends identified for market development include increased healthcare facility development and qualified personnel availability. In addition, there are changes in the culture evident in better health, fitness, and concerns for surgical options among people.

The region is experiencing the growing popularity of intragastric balloons, particularly in countries with high obesity levels. Such treatments are improving owing to affiliations between local service providers and overseas producers. Demand-pull is also being driven by government campaigns toward nutrition, better living, and the fight against obesity. The various types of healthcare delivery systems prevailing across this geography, along with the changing customer dynamics, augur well for further growth in the region’s intragastric balloon market.

Competitive Landscape

The global intragastric balloon market is majorly observed to be in its growing stage and is expected to attract competitive intensity in the future because well-established players are targeting the development of new inventions and diversification of their products. Some of the companies engaged in the market are Apollo Endosurgery, Allergan, which is now a part of AbbVie, and Obalon Therapeutics, which provides various intragastric balloon systems primarily for weight loss. Apollo Endosurgery has increased ORBERA balloon simplification and specialized safety over the last year, indicating an increase in demand for minimally invasive weight management treatments.

Similarly, the INSPIRA balloon used by Allergan has undergone some alterations over the years, including improvements in design and material to try to alleviate issues such as patient pain, among others. In addition, new entrants like Spatz Medical are creating variable balloon technology that discriminates treatment based on the patient's characteristics. The market is also witnessing study connections for intragastric balloons with other therapies such as diet and exercise programs that result in better weight reduction outcomes. All of these advancements represent a broad drive toward the development of sophisticated, personalized, and least-invasive therapies for obesity treatment.

Intragastric Balloon Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In October 2024, Allurion announced that it had submitted the first three modules of its premarket approval (PMA) application for the Allurion Balloon to the U.S. Food and Drug Administration (FDA). The company plans to file the fourth and final module, which will include clinical data from its AUDACITY trial, early in the upcoming year.
• In February 2024, Spatz Medical announced the commercialization of its Spatz3 adjustable gastric balloon. With over 150,000 patients benefiting from the Spatz3 across more than 60 markets worldwide, the company introduced this innovative technology in the U.S. to expand its market presence and further solidify its position in the weight loss solutions sector.

Report Coverage:

By Product Type

• Single Balloon Systems
• Dual Balloon Systems
• Triple Balloon Systems

By Filling Material

• Saline-filled Balloons
• Gas-filled Balloons
• Combination-Filled Balloons

By Insertion Type

• Endoscopic Insertion
• Surgical Insertion
• Non-Endoscopic Insertion

By Material

• Silicone Balloon
• Polyurethane Balloon
• Hybrid

By End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Apollo Endosurgery, Inc.
• Allurion Technologies, Inc.
• Obalon Therapeutics, Inc.
• ReShape Lifesciences, Inc.
• Spatz Medical
• Helioscopie
• Endalis
• MEDSIL
• Silimed
• Lexel Medical
• Districlass Medical
• Medicine
• Medispar
• Shenyun Medical
• Health Ware
• Boston Scientific

Frequently Asked Questions (FAQs)